RGEN · NASDAQ
Repligen Corporation
$175.42 -4.40 (-2.45%)
Company overview
Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing processes in North America, Europe, the Asia Pacific, and internationally. The company offers Protein A ligands, which are the binding components of Protein A affinity chromatography resins, and cell culture growth factor products. Its chromatography products include OPUS pre-packed chromatography columns used in the purification of biologics, as well as smaller-scale OPUS columns used in high throughput process development screening, viral clearance validation studies, and scale down validation of chromatography processes. Repligen also offers ELISA test kits and chromatography resins under the CaptivA brand.
- Sector
- Healthcare
- Industry
- Medical - Instruments & Supplies
- Exchange
- NASDAQ
- Market cap
- $11.1B
- Employees
- 1,778
- Headquarters
- Waltham, MA
- Website
- repligen.com
- CEO
- Olivier Loeillot
- Listed
- April 29, 1986
- P/E
- 193.30
- Dividend yield
- 0.00%
Company financials
- Revenue
- $763M
- Gross profit
- $384M
- Operating income
- $67.3M
- EBITDA
- $183M
- Net income
- $51.4M
- EPS
- $0.91
- Total assets
- $2.9B
- Total debt
- $688M
- Gross margin
- 50.25%
- Net margin
- 6.73%
- Earnings yield
- 0.52%
No geographic segmentation.
Showing FY 2025
RGEN
1D
NASDAQ
O176.93H181.40L176.13C179.82+2.88 (+1.63%)Vol249.45K